Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
12 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Elanco Animal Health reported better-than-expected second-quarter results and raised FY26 guidance above estimates, while Eli Lilly also reported better-than-expected second-quarter results and raised FY26 sales guidance, with the midpoint above estimates.
$LLY Eli Lilly Q2 Earnings
Eli Lilly and Company (NYSE: LLY ) will release its second-quarter earnings report before the opening bell on Wednesday, Aug. 5. Analysts expect the company to report quarterly earnings of $6.58 per share, up from $6.31 per share in the year-ago period. The consensus estimate for Eli Lilly’s quarterly revenue is $20.69
The major averages finished broadly higher as technology shares led gains ahead of a stretch of earnings from some of the market's largest companies. The focus this week is on corporate earnings, with Alphabet, Tesla, IBM and Intel all set to report in the coming days. Investors are looking for signs that spending on a
The major averages closed broadly lower amid a new wave of corporate earnings reports and renewed weakness in the semiconductor space. Earnings season has started off strong this week, as more than 87% of the 40 S&P 500 companies that have already released their results reported positive surprises. Big banks surpassed
() -- Healthcare stocks rose late Wednesday afternoon, with the NYSE Healthcare Index adding 0.3% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 0.1%. The iShares Biotechnology ETF (IBB) added 0.5%. In corporate news, Novo Nordisk (NVO) shares gained 2.9% after it said Wednesday the European C
() -- Healthcare stocks rose Wednesday afternoon, with the NYSE Healthcare Index adding 0.4% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 0.3%. The iShares Biotechnology ETF (IBB) added 0.3%. In corporate news, Novo Nordisk (NVO) shares rose 2.5% after it said Wednesday the European Commissi
() -- Biopharma pricing power will be the key swing factor for Q2 earnings as companies with cleaner growth outlooks continue to outperform peers facing loss-of-exclusivity headwinds, Bank of America said in a note Friday. Merck & Co (MRK), AbbVie (ABBV), Jazz Pharmaceuticals (JAZZ) and Ionis Pharmaceuticals (IONS) rem
() -- Truist Securities revised its model for Eli Lilly (LLY.SW, LLY.F), raising its price target and earnings forecast for the pharmaceutical giant, as analysts anticipate a "beat and raise" second quarter. "We note strong US script growth (Zepbound/ Mounjaro) offset by [slower-than-expected Foundayo growth]. We maint
() -- Eli Lilly (LLY) is expected to deliver Q2 revenue slightly above consensus on stronger-than-anticipated sales of Mounjaro and Zepbound, RBC Capital Markets said Wednesday in a report. RBC forecasts Q2 revenue of about $20.7 billion, ahead of the $20.5 billion consensus estimate, driven by 5% to 6% beats for the d
() -- RBC Capital Markets expects Eli Lilly (LLY.SW) to report a "strong" performance from obesity drugs Zepbound and Mounjaro when it publishes its second-quarter results on Aug. 5. The US-based pharmaceutical company's total revenue is forecast to reach $20.74 billion in the quarter, higher than the Visible Alpha con
JPMorgan raised the firm's price target on Eli Lilly to $1,400 from $1,300 and keeps an Overweight rating on the shares. The firm sees potential upside for Mounjaro from growth in the U.S. obesity market and internationally, the analyst tells investors in a Q2 earnings preview.